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Abstract
CBS deficient individuals undergoing betaine supplementation without suffi-
cient dietary methionine restriction can develop severe hypermethioninemia
and brain edema. Brain edema has also been observed in individuals with
severe hypermethioninemia without concomitant betaine supplementation.
We systematically evaluated reports from 11 published and 4 unpublished
patients with CBS deficiency and from additional four cases of encephalopathy
in association with elevated methionine. We conclude that, while betaine sup-
plementation does greatly exacerbate methionine accumulation, the primary
agent causing brain edema is methionine rather than betaine. Clinical signs of
increased intracranial pressure have not been seen in patients with plasma
methionine levels below 559 μmol/L but occurred in one patient whose levels
did not knowingly exceed 972 μmol/L at the time of manifestation. While
levels below 500 μmol/L can be deemed safe it appears that brain edema can
develop with plasma methionine levels close to 1000 μmol/L. Patients with
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CBS deficiency on betaine supplementation need to be regularly monitored for
concordance with their dietary plan and for plasma methionine concentra-
tions. Recurrent methionine levels above 500 μmol/L should alert clinicians to
check for clinical signs and symptoms of brain edema and review dietary
methionine intake. Levels approaching 1000 μmol/L do increase the risk of
complications and levels exceeding 1000 μmol/L, despite best dietetic efforts,
should be acutely addressed by reducing the prescribed betaine dose.
KEYWORD S
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1 | INTRODUCTION
Methionine is an essential amino acid for humans. Exces-
sive intake, however, causes methionine accumulation.1,2
Hypermethioninemia without dietary excess is also
observed in rare genetic defects of methionine utiliza-
tion3-5 or catabolism.2 Acute severe hypermethioninemia
can be associated with adverse neurological outcomes,
including death.
Betaine (trimethylglycine) is a product of choline catab-
olism and has a role as intracellular organic osmolyte and
methyl donor for the remethylation of homocysteine to
methionine. Betaine supplementation leads to a decrease of
homocysteine and increase in methionine and has been
used for over 40 years in the treatment of genetic defects of
folate-dependent remethylation.6,7 While dietary methio-
nine restriction is sufficient to treat homocystinuria due to
cystathionine beta-synthase deficiency (CBS deficiency,
OMIM # 236200) dietary goals are difficult to achieve and
betaine is often used as adjunctive treatment.8-10
Yaghmai et al11 first reported acute symptomatic
brain edema in a 10-year-old girl with CBS deficiency
who had developed plasma methionine concentrations of
2272-3037 μmol/L after a few weeks of taking betaine
more consistently, without adequate dietary methionine
restriction. The edema was reversible when betaine was
discontinued and strict dietary control instated. Since
then, another five similar cases were published 12-16 as
well as a case of brain edema in a child with methionine
adenosyltransferase (MAT) type I/III deficiency (OMIM
# 250850) on accidental betaine supplementation.17
While there is a causal relationship between betaine sup-
plementation and hypermethioninemia in disorders
affecting the catabolism of methionine, it is not clear
whether brain edema is caused by methionine accumula-
tion or whether increased betaine concentrations are a
contributing factor.
A survey of treatment practices for patients with CBS
deficiency across Europe identified a large proportion of
patients who are on a betaine supplement and 34% of
those apparently without dietary methionine restric-
tion.18 The published cases and additional reports of
adverse outcomes of patients on betaine supplementation
to the license-holder for medicinal betaine under their
post-marketing authorization safety surveillance program
raised concerns about the safety of betaine treatment in
CBS deficiency and prompted a review of the incidence
of brain edema in this population.
2 | METHODS
We performed a literature search to identify patients who
experienced clinical or brain imaging signs of methionine
neurotoxicity, in particular of acute brain edema, with or
without betaine supplementation.
In addition, we approached clinical metabolic special-
ists who participate in a large international email-based
discussion forum (Metab-L, A mailing-list on Inborn Errors
of Metabolism, http://www.metab-l.de) and the sponsor
of the European post-authorization safety study for
betaine19 to identify potential further unpublished cases.
This project was endorsed by the European network for
Homocystinurias and Remethylation Disorders
(E-HOD).
Using a standardized questionnaire, we extracted data
from published articles and from case notes of
unpublished patients with consent from patients or
carers, apart from historic case A2 where this was impos-
sible. Data were anonymized for analysis.
SYNOPSIS
Hypermethioninemia can cause acute encepha-
lopathy and patients with CBS deficiency on
betaine supplementation without sufficient
methionine restriction are at particular risk of
the rare complication of brain edema, once
plasma methionine levels approach 1000 μmol/L.
4 SCHWAHN ET AL.
T
A
B
L
E
1
C
li
n
ic
al
ch
ar
ac
te
ri
st
ic
s
at
di
ag
n
os
is
an
d
ar
ou
n
d
th
e
ep
is
od
e
of
in
cr
ea
se
d
in
tr
ac
ra
n
ia
lp
re
ss
ur
e
of
al
l1
9
pa
ti
en
ts
D
ia
gn
os
is
an
d
tr
ea
tm
en
t
A
cu
te
ep
is
od
e
of
ra
is
ed
IC
P
or
of
w
h
it
e
m
at
te
r
ch
an
ge
s
P
at
ID
Se
x
D
ia
gn
os
is
Sy
m
p
to
m
s
at
D
ia
gn
os
is
A
ge
w
h
en
d
ie
t
st
ar
te
d
A
ge
w
h
en
be
ta
in
e
st
ar
te
d
O
n
se
t
L
at
en
cy
fr
om
ri
se
in
M
et
O
th
er
d
ia
gn
os
es
O
u
tc
om
e
A
1
F
C
B
S
N
B
S
1
w
k
1
y,
st
ri
ct
fr
om
10
y
1
m
o
10
y
6
m
o
8-
10
w
k
P,
ID
F
R
A
2
F
C
B
S
L
en
s
su
bl
u
xa
ti
on
,t
al
ls
ta
tu
re
6
y
6
m
o
6
y
10
m
o
14
y
7
m
o
7
y
9
m
o
P
D
ie
d
A
3
F
C
B
S
L
en
s
su
bl
u
xa
ti
on
,D
D
3
y
2
m
o
3
y
3
m
o
3
y
5
m
o
2-
4
w
k
U
R
T
I,
ID
F
R
A
4
M
C
B
S
L
en
s
su
bl
u
xa
ti
on
,d
ys
pr
ax
ia
4
y
6
m
o
5
y
5
y
6
w
k
2-
4
w
k
N
il
F
R
A
5
F
C
B
S
L
en
s
su
bl
u
xa
ti
on
,I
D
6
y
9
m
o
6
y
10
m
o,
in
cr
ea
se
d
fr
om
6
y
11
m
o
7
y
4
m
o
16
-1
8
w
k
ID
F
R
A
6
F
C
B
S
N
B
S
1
m
o
E
ar
ly
ch
ild
h
oo
d,
ir
re
gu
la
r
24
y
6-
8
w
k
P,
S,
ID
F
R
A
7
M
C
B
S
SS
S
th
ro
m
bo
si
s
4
y
3
w
k
4
y
4
w
k
4
y
4
m
o
10
-1
2
w
k
SS
S
re
m
n
an
t
F
R
A
8
M
C
B
S
N
B
S
1
w
k
2
y,
po
or
co
m
pl
ia
n
ce
fr
om
19
y
21
y
1-
2
y
N
il
F
R
A
9
M
C
B
S
N
B
S
1
m
o
6
m
o,
po
or
co
m
pl
ia
n
ce
2
y
5
m
o
>
20
w
k
N
il
F
R
A
10
M
C
B
S
SS
S
th
ro
m
bo
si
s
an
d
ID
2
y
1
m
o
2
y
3
m
o
2
y
5
m
o
6-
8
w
k
N
il
F
R
A
11
M
M
A
T
I/
II
I
N
B
S,
as
su
m
ed
C
B
S
de
f
3
w
k
3
w
k
3
y
10
m
o
1-
2
y
N
il
F
R
B
1
F
H
ea
lt
h
y
N
/A
N
/A
N
/A
69
y
2
h
A
H
D
ie
d
B
2
M
H
ea
lt
h
y
R
ep
ea
t
N
B
S
N
/A
N
/A
4
m
o
(c
or
r
1
m
o)
6
w
k
Pr
em
at
ur
e
28
w
F
R
B
3
F
H
ea
lt
h
y
M
R
I
br
ai
n
in
cr
it
ic
al
ca
re
N
/A
N
/A
2
w
k
1-
2
w
k
PP
H
N
,T
PN
F
R
C
1
M
C
B
S
St
ro
ke
9
y
2d
af
te
r
di
ag
n
os
is
9
y
N
/A
St
ro
ke
N
/A
C
2
M
C
B
S
ID
,l
ef
t
si
de
d
w
ea
kn
es
s
3
y
N
/A
3
y,
on
D
x
N
/A
ID
F
R
C
3
M
C
B
S
L
en
s
su
bl
u
xa
ti
on
,I
D
7
y
7
y,
po
or
co
m
pl
ia
n
ce
9
y
N
/A
S,
ID
N
/A
C
4
F
C
B
S
L
en
s
su
bl
u
xa
ti
on
,I
D
6
y
6
y,
po
or
co
m
pl
ia
n
ce
7
y
H
ea
da
ch
es
7
y
ID
F
R
C
5
F
C
B
S
D
D
,M
yo
pi
a
3
y
10
m
o
4
y,
po
or
co
m
pl
ia
n
ce
6
y
N
/A
ID
N
/A
A
bb
re
vi
at
io
n
s:
IC
P,
in
tr
ac
ra
n
ia
lp
re
ss
ur
e;
ID
,i
n
te
lle
ct
ua
ld
is
ab
ili
ty
;S
,s
pa
st
ic
it
y
of
li
m
bs
;S
SS
,s
up
er
io
r
sa
gi
tt
al
si
n
us
;P
,p
an
cr
ea
ti
ti
s;
U
R
T
I,
up
pe
r
re
sp
ir
at
or
y
tr
ac
t
in
fe
ct
io
n
;P
P
H
N
,p
er
si
st
en
t
pu
lm
on
ar
y
h
yp
er
te
n
si
on
of
th
e
n
ew
bo
rn
;T
PN
,t
ot
al
pa
re
n
te
ra
ln
ut
ri
ti
on
;A
H
,a
rt
er
ia
lh
yp
er
te
n
si
on
;N
B
S,
G
en
er
al
n
ew
bo
rn
sc
re
en
in
g
pr
og
ra
m
m
e;
F
R
,f
ul
lr
ec
ov
er
y.
SCHWAHN ET AL. 5
3 | RESULTS
A total of 19 cases were identified who, on the back-
ground of hypermethioninemia, either displayed clinical
signs of acute brain edema or who underwent cerebral
imaging and were found to have white matter changes
compatible with edema. These were 15 individuals with
CBS deficiency, 1 with MAT I/III deficiency and three
healthy individuals without a disorder of methionine or
homocysteine metabolism. Appendix 1 contains short
narratives of all patients that could be identified for the
period from 1997 until 2016, that is, over 20 years.
An overview of the patients' clinical characteristics is
provided in Table 1. Relevant dietary and biochemical
data are shown in Table 2 and references are given in
Table 3.
Cases were stratified into three separate groups:
3.1 | Group A
A total of 11 patients with CBS deficiency (Cases A1-A10)
or MAT I/III deficiency (A11) suffered from acute brain
edema in association with hypermethioninemia and beta-
ine supplementation. Five of those cases (A2, A3, A5, A9,
A10) have not or only partly been published before.
The patients' metabolic diagnosis was based on
either general newborn screening programs or following
onset of clinical symptoms between the ages of 2 and
6.75 years. They were started on pyridoxine supplemen-
tation and a methionine restricted diet soon after.
Supplementary betaine was introduced usually a few
months after implementation of dietary and cofactor
treatment, apart from case A11 where it was given from
the time of diagnosis. Brain edema occurred between
6 weeks and 20 years after starting betaine. The latency
between suspected or documented persistent severe
hypermethioninemia and the onset of brain edema was
shorter: 2 weeks to 7 years 9 months, with a median of
9 weeks.
Immediately before and around the time of presenta-
tion, the lowest individual plasma methionine concen-
trations ranged from 559 to 2272 μmol/L (median 1182)
and the highest from 972 to 3154 μmol/L (median 1211).
Plasma concentrations of betaine and its metabolite
dimethylglycine (DMG) on the day of admission to
TABLE 2 Protein and betaine intake and blood metabolites during the acute episode of brain edema
Pat ID Diagnosis
Protein or Met intake
Fold of MSI20
Betaine
dose
(g/day)
Betaine dose
(mg kg−1 day−1)
Met at
presentation
(μmol/L)
tHcy at
presentation
(μmol/L)
A1 CBS 2.25 6 200 2272-3037 263-278
A2 CBS Inconsistent Met restriction 4.5 N/A 1857-3154 N/A
A3 CBS N/A 6 400 1207 260
A4 CBS 1.4 3 150 1190-1205 239
A5 CBS 1.2 4.5 200 1022-1125 116-143
A6 CBS Inconsistent Met restriction 1 N/A 559-1282 266
A7 CBS N/A 6 240 1285 N/A
A8 CBS >2 7.5 N/A 678-1142 167
A9 CBS 0.75 4.1 340 1182-1211 148-203
A10 CBS N/A 2 107 738-972 120
A11 MAT I/III Inconsistent Met restriction Unknown N/A 960-1560 6-15
B1 Healthy 60-80 (single dose of 80 g Met) Nil Nil 4640-5760 25-43
B2 Healthy 4 (276 mg/kg per day from 2 mo 3wk) Nil Nil 2326-6830 44
B3 Healthy 10 (507 mg/kg per d) Nil Nil 1300-2154 27
C1 CBS Unrestricted diet 6 N/A 433 (10d after adm) N/A
C2 CBS Inconsistent Met restriction Unknown N/A 1082 175
C3 CBS Inconsistent Met restriction 5 N/A 495 at dx 154 at dx
C4 CBS Inconsistent Met restriction Unknown N/A 622 at dx 173 at dx
C5 CBS Inconsistent Met restriction 8 N/A N/A N/A
Abbreviations: MSI, minimum safe intake; tHcy, plasma total homocysteine; Met, plasma methionine.
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hospital were available for three cases, A4, A5, and
A9: Betaine was 98, 131, and 40 μmol/L and DMG was
64, 43, and 24 μmol/L, respectively. All were within
the expected trough range under treatment.6 CSF con-
centrations were available for two cases: in patient
A4 methionine was 235 and betaine 6.6 μmol/L; in
patient A9 methionine was 199, betaine 0.12 and DMG
1.55 μmol/L.
Treatment of brain edema consisted of unspecific
measures to lower intracranial pressure and of tighter
dietary restriction of methionine. Betaine was temporar-
ily stopped in seven patients (A1, A3, A4, A5, A8, A10,
A11) and the dose halved in two patients (A6, A9). The
other two patients (A2, A7) remained on an unchanged
dose while being treated for edema. Betaine was later re-
introduced in four of the seven temporarily discontinued
patients (A3, A5, A8, and A10). There was no recurrence
of brain edema in the seven surviving patients who con-
tinued on long term betaine supplementation. Betaine
doses were not always detailed, known doses ranged
from 100 to 400 mg kg−1 day−1 or 1.0 to 7.5 g day−1
(Table 2).
All patients except A2 survived and completely
recovered from brain edema. Patient A2 was admitted
with acute severe pancreatitis but also displayed
abnormal movements and was found to have the
hypodense white matter on CT brain scan. She died
from multiorgan failure. Post mortem examination
demonstrated increased brain weight and spongiosis.
The contribution of brain edema to the fatal outcome
is unclear.
3.2 | Group B
Acute brain edema was observed in two healthy infants
at the age of 2 weeks and 4 months, respectively, who
had been on an inappropriately high oral intake of pro-
tein from formula feeds.21 They were diagnosed acciden-
tally after a respective exposure of 1 and 6 weeks long to
methionine plasma concentrations of 1300-6830 μmol/L.
Both recovered on adjusting their feeds.
The third healthy individual who experienced acute
methionine neurotoxicity was reported by Cottington
et al.1 Patient B1, a healthy woman of 69 years, deterio-
rated with signs of encephalopathy within 2 hours of a
methionine loading test. Her plasma methionine reached
concentrations of up to 5760 μmol/L. The authors
suspected an accidental 10-fold methionine overdose
as the most likely reason for her excessive hyper-
methioninemia. She died after a prolonged and compli-
cated comatose state.
3.3 | Group C
Further five cases have been reported of patients with
longstanding hypermethioninemia due to CBS deficiency
and various degrees of cerebral white matter signal
changes compatible with edema.
Case 1 (C1) developed acute brain edema due to cere-
bral venous thrombosis prior to diagnosis of CBS defi-
ciency and before betaine was administrated
[unpublished]. Case 2 (C2) had white matter signal
changes that resolved on initiation of dietary treatment
and betaine supplementation.22 Three other patients on
dietary and medical treatment, including betaine, but
with apparently inconsistent adherence to treatment (C3,
C4, and C5) were found to have white matter changes on
imaging. In one patient (C4) these were associated with
clinical signs compatible with raised intracranial pressure
and resolved with time.23 Unfortunately, the case reports
for patients C3, C4, and C5 lack further clinical and bio-
chemical detail.
In Group C, patients had maximum documented
plasma concentrations of methionine ranging from
433 to 1082 and of total homocysteine from 154 to
175 μmol/L.
TABLE 3 References for patient data
Pat ID Diagnosis Reference
A1 CBS 11
A2 CBS J. Fletcher, personal communication
A3 CBS A. Das, personal communication
A4 CBS 12
A5 CBS T. Scheffner, personal communication
A6 CBS 16
A7 CBS 13
A8 CBS 15
A9 CBS 14
A10 CBS H Stepman and P Verloo,
personal communication
A11 MAT I/III 17
B1 Healthy 1
B2 Healthy 21
B3 Healthy 21
C1 CBS 19
C2 CBS 22
C3 CBS 23
C4 CBS 23
C5 CBS 23
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Betaine doses in this group were not always given in
detail; known doses ranged from 5 to 8 g day−1.
4 | DISCUSSION
The acute and long-term toxicity of methionine excess
has been studied for decades.24 When acute brain edema
in a patient with CBS deficiency and high methionine
concentrations under betaine supplementation was first
described, the role of betaine as an organic osmolyte
raised suspicion that an excess of betaine rather than of
methionine may cause edema. Betaine, however, has
low toxicity and has been administered in high doses,
up to 20 g per day, in patients with homocysteine
remethylation defects without adverse effects. After oral
dosing betaine has a short distribution half-life of
0.6 hours.6,25 Plasma concentrations vary from normal
(20-60 μmol/L) to above 2800 μmol/L during typical dos-
ing.6,26,27 Plasma betaine concentrations are not routinely
monitored. We were able to retrieve data from patients
A4, A5, and A9 whose plasma betaine concentrations
levels were not elevated at the time of presentation with
brain edema. The available concentrations of betaine and
DMG in CSF were very low and do not indicate any accu-
mulation of betaine. Animal studies suggest that brain
tissue stores only small amounts of betaine.28,29 The beta-
ine transporter BGT-1 is expressed in leptomeninges
but is only poorly expressed in neuronal or glial cells and
a recent review concluded that the contribution of beta-
ine to maintaining brain cellular volume is probably
insignificant.30
Amino acid transport across brain diffusion barriers
involves saturable carriers and non-saturable diffusion
(Smith et al. 1987). Methionine in very high concentra-
tions can displace other neutral amino acids from high-
affinity carriers (reviewed by Chien et al.4) causing
preferential uptake and a relative lack of other essential
substrates in the brain. Furthermore, at very high
plasma concentrations significant amounts of methio-
nine may enter the brain cells via low-affinity carriers32
or by simple diffusion. CSF concentrations of methio-
nine are normally below 10 μmol/L but reached over
20-fold higher concentrations in patients A4 and A9.
Short term increases in plasma methionine concentra-
tions to a range of 700-1800 μmol/L, such as seen during
a typical L-methionine loading test, frequently lead to
mild encephalopathy manifesting as dizziness, sleepi-
ness, and nausea.33,34 Methionine-induced increased oxi-
dative stress and inhibition of synaptic Na+,K+-ATPase,
which is required to regulate neuronal cell volume, has
been suggested by a number of authors11,21,35 as the
most plausible explanation for the development of brain
edema.
Our search identified further cases of brain edema in
patients with hypermethioninemia under betaine supple-
mentation (group A). However, brain edema also
occurred in patients with severe hypermethioninemia
without concomitant betaine treatment (group B). A few
patients (group C) were included who demonstrated
signs of white matter disease after long-term exposure
to increased methionine concentrations, indicating the
possibility of chronic methionine neurotoxicity. White
matter lesions in CBS deficiency can represent both dys-
myelination and intramyelinic edema. The reversibility
of such lesions in cases C2 and C4 and as reported by
Franco et al36 suggests the presence of edema.
These observations lead to the conclusion that methi-
onine is the primary toxic agent causing brain edema,
and not betaine. Even mildly impaired CBS activity
reduces the capacity to metabolize methionine.34 Without
adequate methionine restriction betaine supplementation
greatly exacerbates methionine accumulation in patients
with CBS deficiency and becomes a permissive factor for
the development of brain edema.
We were able to identify only 16 cases of manifest
brain edema in patients with CBS deficiency over a
period of 20 years. The relative rarity of this complication
despite a considerable prevalence of severe hyper-
methioninemia indicates a low relative risk and addi-
tional precipitating factors. Most episodes of edema
occurred shortly after starting or increasing the betaine
supplement, which suggests that acute changes are more
dangerous than chronic hypermethioninemia. On the
other hand, not all patients showed clear clinical symp-
toms and some cases may have been overlooked. It is pos-
sible that a higher susceptibility to edema is conferred by
variations in cerebral methionine transport or synaptic
Na+,K+-ATPase in some individuals but this has not
been tested.
In the reported cases, methionine plasma concentra-
tions were not always frequently enough recorded to
allow firm conclusions about a threshold above which
edema can develop. Around the time of manifestation,
none of the individuals with brain edema had a plasma
methionine lower than 559 μmol/L. Edema was however
observed in one patient whose recorded maximum level
was 972 μmol/L. While levels below 500 μmol/L can be
deemed safe, it appears that brain edema can develop
with plasma methionine concentrations below
1000 μmol/L. It is not safe to aim for plasma levels below
1500 μmol/L as suggested previously11 but rather below
1000 μmol/L, in accordance with recently published
guidance.9
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5 | RECOMMENDATION
Patients with CBS deficiency on betaine supplementation
need to be regularly monitored for concordance with
their dietary plan and for plasma methionine concentra-
tions. Recurrent levels above 500 μmol/L should alert cli-
nicians to check for clinical signs and symptoms of brain
edema and review the dietary methionine intake. Levels
approaching 1000 μmol/L do increase the risk of compli-
cations and levels exceeding 1000 μmol/L, despite the
best dietetic efforts, should be acutely addressed by
reducing the prescribed betaine dose.
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SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of this
article.
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